Search results for: Genetic
Filter search results
Amanda Cole
30 May 2014
…research agenda for how real-world evidence can improve healthcare technology development and adoption. Amanda has a special interest in rare diseases and serves on several advisory groups, including Genetic Alliance…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
…managers. Germany’s financial institutions and its laws governing genetic engineering, intellectual property, and employment created longstanding institutional obstacles to the development of high-technology industries and markets for venture capital and…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
…view other videos from the Translation Genomics Event presented by the NHS’s National Genetics Education and Development Centre click here. Challenges in Valuing Genomic Medicines from Office of Health Economics…
Sukanya Subramaniyan
3 October 2024
…at the University of Cambridge. Her master’s thesis investigated the association between rare germline genetic variation and the risk of epithelial ovarian cancer. Sukanya’s current research interests include modelling methods…
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
…a paradigm shift in medicine, offering the potential for significant improvements in both quality and longevity of life, by addressing the root genetic causes of diseases. Due to this potential…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…7,000 (known) rare conditions, 80% of which have a genetic cause. The definition of “rare” means that a disease impacts fewer than one in 2,000 people, but the majority of…
OHE Lunchtime Seminar: Early Experience with HTA of Gene Therapies in the US: Pricing and Paying for Cures
21 October 2018, 11:00pm
…haemophilia, sickle cell disease, and numerous other genetically-based conditions. Individually, each treatment will be extremely expensive, and in the aggregate their costs are projected to have a substantial impact on…
AIDS: Worldwide Policies and Problems
1 September 1991
…been learnt about its pathogenic mechanisms. Since the virus is integrated into genetic material and therefore replicates itself, it is very difficult to intervene in terms of vaccines or therapies….
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…offer improvement for patients. Taking the second and third factors into account, ICER’s panel majority found Luxturna, for genetic retinal disease causing blindness, to represent “intermediate long term value for…